收费全文 | 1367846篇 |
免费 | 98279篇 |
国内免费 | 3034篇 |
耳鼻咽喉 | 20091篇 |
儿科学 | 40980篇 |
妇产科学 | 39345篇 |
基础医学 | 191385篇 |
口腔科学 | 40710篇 |
临床医学 | 116219篇 |
内科学 | 269392篇 |
皮肤病学 | 30583篇 |
神经病学 | 109160篇 |
特种医学 | 54792篇 |
外国民族医学 | 436篇 |
外科学 | 213856篇 |
综合类 | 31496篇 |
现状与发展 | 6篇 |
一般理论 | 460篇 |
预防医学 | 94767篇 |
眼科学 | 32387篇 |
药学 | 102198篇 |
3篇 | |
中国医学 | 3024篇 |
肿瘤学 | 77869篇 |
2018年 | 12446篇 |
2016年 | 11144篇 |
2015年 | 12559篇 |
2014年 | 17677篇 |
2013年 | 26752篇 |
2012年 | 35145篇 |
2011年 | 37090篇 |
2010年 | 21999篇 |
2009年 | 21431篇 |
2008年 | 35575篇 |
2007年 | 38746篇 |
2006年 | 39332篇 |
2005年 | 38234篇 |
2004年 | 37248篇 |
2003年 | 36067篇 |
2002年 | 35475篇 |
2001年 | 63883篇 |
2000年 | 65557篇 |
1999年 | 55729篇 |
1998年 | 15114篇 |
1997年 | 13837篇 |
1996年 | 13252篇 |
1995年 | 12520篇 |
1994年 | 11717篇 |
1992年 | 42975篇 |
1991年 | 41477篇 |
1990年 | 40709篇 |
1989年 | 39699篇 |
1988年 | 37120篇 |
1987年 | 36560篇 |
1986年 | 35051篇 |
1985年 | 33272篇 |
1984年 | 25072篇 |
1983年 | 21290篇 |
1982年 | 12985篇 |
1981年 | 11859篇 |
1979年 | 24071篇 |
1978年 | 17241篇 |
1977年 | 15011篇 |
1976年 | 13558篇 |
1975年 | 15401篇 |
1974年 | 18195篇 |
1973年 | 17697篇 |
1972年 | 16916篇 |
1971年 | 15781篇 |
1970年 | 14987篇 |
1969年 | 14400篇 |
1968年 | 13507篇 |
1967年 | 12045篇 |
1966年 | 11295篇 |
Areas covered: the principal pharmacogenetic and non-genetic differences in the pharmacology of tamoxifen and endoxifen are evaluated. To this end, references from PubMed, Embase or Web of Science, among others, were reviewed As non-genetic factors, important differences and similarities such age, or adherence to tamoxifen therapy are comprehensively illustrated. Additionally, since CYP2D6 genotypes are considered the main limitation of tamoxifen, many studies have investigated the association between the worsened clinical outcomes in patients with non-functional CYP2D6 genotypes. In this review, an overview of the research on this field is presented. Also, a summary describing the literature about individualizing tamoxifen therapy with endoxifen concentrations and its limitations is listed.
Expert opinion: z-endoxifen hydrochloride is only investigated in the metastatic setting, still more research is required before its place in therapeutics is known. Similarly, monitoring tamoxifen efficacy based on endoxifen concentrations might not be overall recommended due to the limited evidence available. 相似文献
The metabolism of the pyrethroids deltamethrin (DLM), cis-permethrin (CPM) and trans-permethrin (TPM) was studied in human expressed cytochrome P450 (CYP) and carboxylesterase (CES) enzymes.
DLM, CPM and TPM were metabolised by human CYP2B6 and CYP2C19, with the highest apparent intrinsic clearance (CLint) values for pyrethroid metabolism being observed with CYP2C19. Other CYP enzymes contributing to the metabolism of one or more of the three pyrethroids were CYP1A2, CYP2C8, CYP2C9*1, CYP2D6*1, CYP3A4 and CYP3A5. None of the pyrethroids were metabolised by CYP2A6, CYP2E1, CYP3A7 or CYP4A11.
DLM, CPM and TPM were metabolised by both human CES1 and CES2 enzymes.
Apparent CLint values for pyrethroid metabolism by CYP and CES enzymes were scaled to per gram of adult human liver using abundance values for microsomal CYP enzymes and for CES enzymes in liver microsomes and cytosol. TPM had the highest and CPM the lowest apparent CLint values for total metabolism (CYP and CES enzymes) per gram of adult human liver.
Due to their higher abundance, all three pyrethroids were extensively metabolised by CES enzymes in adult human liver, with CYP enzymes only accounting for 2%, 10% and 1% of total metabolism for DLM, CPM and TPM, respectively.